Brokerages expect Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) to announce ($0.42) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Aldeyra Therapeutics’ earnings, with estimates ranging from ($0.50) to ($0.36). Aldeyra Therapeutics posted earnings of ($0.38) per share in the same quarter last year, which would suggest a negative year over year growth rate of 10.5%. The firm is scheduled to announce its next earnings results on Monday, November 13th.

According to Zacks, analysts expect that Aldeyra Therapeutics will report full year earnings of ($1.67) per share for the current year, with EPS estimates ranging from ($2.12) to ($1.43). For the next fiscal year, analysts anticipate that the business will post earnings of ($1.75) per share, with EPS estimates ranging from ($2.49) to ($1.24). Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Aldeyra Therapeutics.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.02.

A number of equities analysts recently weighed in on ALDX shares. HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 15th. ValuEngine lowered shares of Aldeyra Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 6th. Cowen and Company reiterated an “outperform” rating and issued a $14.00 price objective (up from $9.00) on shares of Aldeyra Therapeutics in a research report on Thursday, September 14th. Canaccord Genuity reiterated a “buy” rating and issued a $27.00 price objective (up from $12.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, September 13th. Finally, Zacks Investment Research lowered shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. Aldeyra Therapeutics currently has a consensus rating of “Buy” and an average price target of $15.95.

COPYRIGHT VIOLATION WARNING: “Aldeyra Therapeutics, Inc. (ALDX) Expected to Announce Earnings of -$0.42 Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/10/05/aldeyra-therapeutics-inc-aldx-expected-to-announce-earnings-of-0-42-per-share-2.html.

Aldeyra Therapeutics (NASDAQ:ALDX) traded up 1.31% during trading on Thursday, hitting $7.75. 230,378 shares of the company traded hands. The firm’s market cap is $48.40 million. Aldeyra Therapeutics has a 52-week low of $3.80 and a 52-week high of $11.90. The company’s 50-day moving average is $5.89 and its 200 day moving average is $4.98.

In related news, major shareholder Life Sciences Maste Perceptive bought 200,000 shares of the firm’s stock in a transaction on Tuesday, September 19th. The shares were bought at an average cost of $7.25 per share, for a total transaction of $1,450,000.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 28.40% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Aldeyra Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 304,633 shares of the biotechnology company’s stock worth $1,431,000 after purchasing an additional 9,407 shares in the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth $104,000. Renaissance Technologies LLC purchased a new stake in shares of Aldeyra Therapeutics during the 1st quarter worth $132,000. Hikari Power Ltd boosted its position in shares of Aldeyra Therapeutics by 186.4% during the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after purchasing an additional 70,196 shares in the last quarter. Finally, Sabby Management LLC purchased a new stake in shares of Aldeyra Therapeutics during the 1st quarter worth $898,000. Institutional investors own 40.06% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.

Get a free copy of the Zacks research report on Aldeyra Therapeutics (ALDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.